

Thursday September 17th

8:00am - 10:00am: Session I: HDL structure/composition and function

Moderator: John Parks, Wake Forest University

Allison Weckerle, Wake Forest
Is apoL1 really an HDL apolipoprotein?

Ryan Temel, University of Kentucky
Impact of hepatic NPC1L1 and ABCG5/G8 on atherosclerosis and RCT

Sean Davidson, University of Cincinnati
The influence of HDL structure on its function

John Stafford, Vanderbilt University
Liver pathways that influence HDL composition and function in obesity

10:00am-10:30 am: Break

10:30am – 12:30pm: Session II: Noncoding RNAs in Physiology & Therapeutics

Kasey C Vickers, Vanderbilt Univ. School of Medicine
Lipoprotein Transport of small RNAs in Familial Hypercholesterolemia

Daping Fan, Univ. of South Carolina School of Medicine
The Role of miR-155 in Atherogenesis and Beyond

Bailey Peck *Graduate Student*, Univ. of North Carolina-Chapel Hill.
Investigating microRNA Regulatory Networks in the Intestinal Epithelium

Jonathan Haldeman, Duke Univ. School of Medicine.
The Function and Regulation of the miR-17~92 Cluster in the Pancreatic Beta-Cell

12:30pm – 5:30pm: Free Time Early Career Programming

Trainee Networking Social Hour

5:30pm – 7:30pm: Poster Session & Reception

8:00pm – 9:00pm: W. Virgil Brown Keynote Lecture

Dietary Fatty acids and the metabolic syndrome

Nada Abumrad

Robert C. Atkins Professor of Obesity Research in Medicine
Washington University School of Medicine in St. Louis

Friday, September 18th

8:00am -10:00 am: Session III: Macrophages and the Microenvironment

Moderator, Liza Makowski (Chair-UNC)

Norbert Leitinger, University of Virginia

Metabolism and inflammatory state of adipose tissue macrophages

Bill Zamboni, University of North Carolina

Bi-directional interaction between mononuclear phagocyte system and liposomal and carrier-mediated agents in preclinical models and patients

Alyssa Hasty, Vanderbilt University

A novel role for adipose tissue macrophages in iron metabolism

10:00am -10:30am: Break

10:30am – 12:00pm: Session III: Emerging Therapies in Clinical Cardiology

Moderator: Virgil Brown, Emory University

James Revkin, Pfizer Inc.

Clinical Trial Results with PCSK9 mAbs

Chip Davis, CVPath Institute

The long and winding road of Ezetimibe

Chip Davis, CVPath Institute

The Improve-IT Trial

Virgil Brown, Emory University

Recent Clinical Guidelines in Lipid Lowering

12:00pm – 5:30pm: Free Time & Early Career Programming

Job Talks

Trip to Aquarium?

5:30pm – 7:30pm: Session V: Computational Applications in Cardiometabolic Disease

Moderator: Alison Motsinger-Reif, North Carolina State University

Alison Motsinger-Reif, North Carolina State University

Stella Aslibekyen, University of Alabama, Birmingham

Saturday, September 19th

8:00am -10:00am: Session VI: Bile Acids, Physiology to Therapeutics

Moderator: Paul Dawson Emory University

Saul Karpen, Emory University
Bile Acids and Fatty Liver

Grace Guo, Rutgers University
FXR signaling

Phil Hylemon, Virginia Commonwealth University
Bile Acid Signaling in the Liver

David Shapiro, Intercept Pharmaceuticals
Bile Acids in the treatment of liver disease

10:00am -10:30am: Break

10:30 – 12:30: Session VII: Regulation of lipogenesis and fatty acid oxidation

Moderator: Edwards Park (Chair- UTHSC)

Thurl Harris, University of Virginia
mTORC and TG metabolism

Dave Bridges, University of Tennessee Health Science Center
mTORC and insulin signaling

Randall Mynatt, Louisiana State University, Pennington
CPT1b in lipid metabolism